Key Figures

	2022¹	2021¹
Earnings	Mio. Euro	Mio. Euro
Sales revenue	18.5	1.7
Other income	1.4	0.6
Operating expenses	(37.0)	(27.9)
Operating result	(17.2)	(25.6)
Earnings before tax	(17.8)	(26.1)
Total comprehensive income	(19.7)	(26.1)
Earnings per share in EUR	(0.53)	(0.80)

Balance sheet as of 30.11.
Total assets	100.6	21.7
Cash and cash equivalents	81.3	6.1
Equity	66.6	6.7
Equity ratio² in %	66.3	30.8

Cash flow
from operating activities	(8.9)	(26.6)
from investing activities	(0.6)	(1.4)
from financing activities	84.0	29.2

Employees
Employees as of 30.11.³	110	96

¹ The reporting period begins on 1 December and ends on 30 November
² Equity / total assets
³ Including members of the Executive Management Board

Outlook

	Plan 2023 EUR million
Sales revenue and other income	7.0 – 10.0
Operating expenses	37.0 – 41.0
Operating result (EBIT)	(28.5) – (32.5)
Total funding requirement¹	32.5 – 36.5
Funds required per month¹	2.7 – 3.1

¹ Not including any corporate actions

© Heidelberg Pharma AG. All rights reserved.